REM sleep behavior disorder (RBD), formally recognized in the 1980s, is an infrequent but spectacular parasomnia characterized by dream enactment, leading to aggressive or complex behaviors. It essentially affects older men, and many years may go by before medical attention is sought. Frequent association with the alpha-synucleinopathies,-such as Parkinson disease, has led investigators to believe that idiopathic RBD is not necessarily a benign condition. Diagnosis is confirmed with a polysomnogram, which typically shows absence of normal REM sleep atonia and sometimes abnormal behavior. Treatment is achieved with clonazepam.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.mcna.2010.02.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biomarkers that aid in early detection of neurodegeneration are needed to enable early symptomatic treatment and enable identification of people who may benefit from neuroprotective interventions. Increasing evidence suggests that sleep biomarkers may be useful, given the bi-directional relationship between sleep and neurodegeneration and the prominence of sleep disturbances and altered sleep architectural characteristics in several neurodegenerative disorders. This study aimed to demonstrate that sleep can accurately characterize specific neurodegenerative disorders (NDD).
View Article and Find Full Text PDFPrediction of Phenoconversion into Alpha-Synucleinopathy in Patients with isolated REM Sleep Behavior Disorder Using Event-Related Potentials During Visuospatial Attention Tasks.
Sleep
December 2024
Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
Study Objectives: Isolated REM sleep behavior disorder (iRBD) is recognized as a prodromal stage of alpha-synucleinopathies. Predicting phenoconversion in iRBD patients remains a key challenge. We aimed to investigate whether event-related potentials (ERPs) recorded during visuospatial attention task can serve as predictors of phenoconversion in iRBD patients.
View Article and Find Full Text PDFOfatumumab treatment in new-onset narcolepsy type 1 following SARS-CoV-2 infection.
Ann Clin Transl Neurol
December 2024
Department of Neurology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Objectives: To explore the efficacy of ofatumumab in new onset narcolepsy type 1 following SARS-CoV-2 infection.
Methods: We present a 9-year-old girl who experienced new onset narcolepsy type 1 following SARS-CoV-2 infection. Polysomnography (PSG) followed by a daytime multiple sleep latency test (MSLT) was under taken after admission.
Objectives: This retrospective study aims to evaluate the efficacy of continuous positive airway pressure (CPAP) therapy in treating severe obstructive sleep apnea (OSA), based on polysomnographic parameters, and to highlight the importance of hospital-based titration in optimizing treatment and guiding choices of alternative ventilation modes.
Methods: Sixty-nine patients (n=69, 100%), predominantly female (n=49, 71%), were included in the study. Polysomnographic data were collected during hospital-based CPAP titration.
Aperiodic neural activity distinguishes between phasic and tonic REM sleep.
J Sleep Res
December 2024
Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behavior, Nijmegen, Netherlands.
Traditionally categorized as a uniform sleep phase, rapid eye movement sleep exhibits substantial heterogeneity with its phasic and tonic constituents showing marked differences regarding many characteristics. Here, we investigate how tonic and phasic states differ with respect to aperiodic neural activity, a marker of arousal and sleep. Rapid eye movement sleep heterogeneity was assessed using either binary phasic-tonic (n = 97) or continuous (in 60/97 participants) approach.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!